Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Oxford Pharmascience passes statins formulation milestone

Oxford Pharmascience passes statins formulation milestone

Oxford Pharmascience (LON:OXP) has successfully completed the formulation development for its Safestat formulations of Atorvastatin and Simvastatin, the leading generic statin drugs.

The company said it has proven in-vitro release under simulated human conditions.

The Safestat programme aims to reformulate the widely used molecules of atorvastatin and simvastatin into doses one quarter of the original dose without lowering the effectiveness of the cholesterol reducing drugs.

The statins market is a huge one, valued at more than US$29bn in 2009, but many patients report side effects from their use; reducing the dosage may enable more people to use the drugs.

"Completion of formulation development is a first important milestone in the Safestat programme and we are now ready to proceed to manufacture of GMP [good manufacturing practice] products for use in proof of concept clinical trials during 2013," said Marcelo Bravo, chief technology officer of Oxford Pharmascience.

John-H.jpg


Register here to be notified of future OXP Company articles
View full OXP profile

Oxford Pharmascience Timeline

Related Articles

Knee.jpg
February 14 2017
It has unveiled plans to raise as much as £12mln, which should transform the business.
viagra2.jpg
September 07 2016
It means Futura now has a differentiated product in a market worth US$5bn that , currently dominated by top-selling drugs, such as Viagra and Cialis, that have limitations.
hepatitisC.jpg
March 27 2017
Regulatory sign-off will fire the starting pistol on the commercial launch in Europe

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use